Paclitaxel modulates TGFβ signaling in scleroderma skin grafts in immunodeficient mice

PLoS Medicine

Volumn 2, Issue 12, 2005, Pages 1334-1342

  Liu, Xialin ^a   Zhu, Shoukang ^a   Wang, Tao ^a   Hummers, Laura ^b   Wigley, Fredrick M ^b   Goldschmidt Clermont, Pascal J ^a   Dong, Chunming ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; COLLAGEN; PACLITAXEL; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; SMAD PROTEIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FIBROSIS; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN GRAFT; SYSTEMIC SCLEROSIS; TRANSPLANTATION; ANIMAL; BIOPSY; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; XENOGRAFT;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROSIS; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PHENOTYPE; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

EID: 29644432536     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020354     Document Type: Article

References (30)

1. LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis. 51: 286-288.
2. Kissin EY, Korn JH (2003) Fibrosis in scleroderma. Rheum Dis Clin North Am 29: 351-369.
3. Kahaleh MB, LeRoy EC (1999) Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31: 195-214.
4. Branton MH, Kopp JB (1999) TGF-beta and fibrosis. Microbes Infect 1: 1349-1365.
5. Wigley FM, Sule SD (2001) Novel therapy in the treatment of scleroderma. Expert Opin Investig Drugs 10: 31-48.
6. Pollman MJ, Naumovski L, Gibbons GH (1999) Vascular cell apoptosis: Cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. Circulation 99: 2019-2026.
7. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
8. Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ (2000) Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 5: 27-34.
9. Dong C, Zhu S, Wang T, Yoon W, Li Z, et al. (2002) Deficient Smad7 expression: A putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99: 3908-3913.
10. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590.
11. Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T (2000) Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 39: 1110-1113.
12. Sgonc R (1999) The vascular perspective of systemic sclerosis: Of chickens, mice and men. Int Arch Allergy Immunol 120: 169-176.
13. Lakos G, Takagawa S, Chen S, Ferreira AM, Han G, et al. (2004) Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165: 203-217.
14. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, et al. (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18: 1280-1291.
15. Feinberg MW, Shimizu K, Lebedeva M, Haspel R, Takayama K, et al. (2004) Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res 94: 601-608.
16. Zhao J, Shi W, Wang YL, Chen H, Bringas P, et al. (2002) Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 282: L585-593.
17. Flanders KC (2004) Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85: 47-64.
18. Zhu S, Goldschmidt-Clermont PJ, Dong C (2004) Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ Res 94: 617-625.
19. Brahn E, Tang C, Banquerigo ML (1994) Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum 37: 839-845.
20. Cao L, Sun D, Cruz T, Moscarello MA, Ludwin SK, et al. (2000) Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J Neuroimmunol 108: 103-111.
21. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675-694.
22. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, et al. (2003) Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 108: 457-463.
23. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, et al. (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49.
24. Goldschmidt-Clermont PJ (2003) Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis. Am Heart J 146: S5-12.
25. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364: 603-610.
26. Distler O, Distler JH, Scheid A, Acker T, Hirth A, et al. (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95: 109-116.
27. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, et al. (2002) Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4: R11.
28. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S (2002) Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res 90: E89-E93.
29. Del Papa N, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, et al. (2004) Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50: 1296-1304.
30. Thatte U, Bagadey S, Dahanukar S (2000) Modulation of programmed cell death by medicinal plants. Cell Mol Biol (Noisy-le-grand) 46: 199-214.